The journey from laboratory innovation to bedside care requires rigorous validation, regulatory clearance, and scalable production. Translational and clinical applications in regenerative medicine emphasize how preclinical successes evolve into clinically viable therapies. It involves refining delivery systems, validating efficacy in human models, and aligning treatments with patient-specific needs. Technologies like 3D-printed grafts, cell-based therapies, and gene-modified tissues are now being tested in controlled trials. Translational and clinical applications also address manufacturing challenges, ethical oversight, and physician training to ensure successful implementation. As more therapies reach early-phase and advanced clinical stages, the path to accessible and reliable regenerative solutions is becoming clearer and more standardized globally.
Title : Eliminating implants infections with nanomedicine: Human results
Thomas J Webster, Interstellar Therapeutics, United States
Title : Biodistribution and gene targeting in regenerative medicine
Nagy Habib, Imperial College London, United Kingdom
Title : Graphene, butterfly structures, and stem cells: A revolution in surgical implants
Alexander Seifalian, Nanotechnology & Regenerative Medicine Commercialisation Centre, London NW1 0NH, United Kingdom
Title : Precision in cartilage repair: Breakthroughs in biofabrication process optimization
Pedro Morouco, Polytechnic of Leiria, Portugal
Title : Keratin-TMAO wound dressing promote tissue recovery in diabetic rats via activation of M2 macrophages
Marek Konop, Medical University of Warsaw, Poland
Title : Assessing geometric simplifications in vertebral modeling for reliable numerical analysis of intervertebral discs
Oleg Ardatov, Vilnius University, Lithuania